Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108095 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 701
- Enrollment target
NCT00108095: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00108095 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 701 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (427% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108095, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 701 participants
- Enrollment target
Study Summary
This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
Interventions
- DRUG intravenous ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00108095 record still lists
NCT00108095 is an interventional study that assigns participants to a tested intervention. The registered 701 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (427% higher).
The record links to 0 conditions, and to 1 intervention - of which intravenous ondansetron is the first listed.
NCT00108095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00108095 about?
NCT00108095 is a clinical study titled "A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting". This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
What is the current status of trial NCT00108095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 701 participants. The study started on 2004-10. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00108095?
The interventions under investigation include: intravenous ondansetron (DRUG).
Who is sponsoring clinical trial NCT00108095?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00108095's enrollment target sits among peer trials
701 46th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia